Literature DB >> 30216468

Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper.

Marek L Kowalski1, Ioana Agache2, Sevim Bavbek3, Arzu Bakirtas4, Miguel Blanca5, Grażyna Bochenek6, Matteo Bonini7, Enrico Heffler8, Ludger Klimek9, Tanya M Laidlaw10, Joaquim Mullol11, Ewa Niżankowska-Mogilnicka6, Hae-Sim Park12, Marek Sanak13, Mario Sanchez-Borges14, Silvia Sanchez-Garcia15, Glenis Scadding16, Masami Taniguchi17, Maria J Torres18, Andrew A White19, Aleksandra Wardzyńska1.   

Abstract

NSAID-exacerbated respiratory disease (N-ERD) is a chronic eosinophilic, inflammatory disorder of the respiratory tract occurring in patients with asthma and/or chronic rhinosinusitis with nasal polyps (CRSwNP), symptoms of which are exacerbated by NSAIDs, including aspirin. Despite some progress in understanding of the pathophysiology of the syndrome, which affects 1/10 of patients with asthma and rhinosinusitis, it remains a diagnostic and therapeutic challenge. In order to provide evidence-based recommendations for the diagnosis and management of N-ERD, a panel of international experts was called by the EAACI Asthma Section. The document summarizes current knowledge on the pathophysiology and clinical presentation of N-ERD pointing at significant heterogeneity of this syndrome. Critically evaluating the usefulness of diagnostic tools available, the paper offers practical algorithm for the diagnosis of N-ERD. Recommendations for the most effective management of a patient with N-ERD stressing the potential high morbidity and severity of the underlying asthma and rhinosinusitis are discussed and proposed. Newly described sub-phenotypes and emerging sub-endotypes of N-ERD are potentially relevant for new and more specific (eg, biological) treatment modalities. Finally, the document defines major gaps in our knowledge on N-ERD and unmet needs, which should be addressed in the future.
© 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.

Entities:  

Keywords:  AERD; ENT (rhinitis, sinusitis, nasal polyps…); asthma; asthma treatment; drug allergy; sinusitis

Mesh:

Substances:

Year:  2018        PMID: 30216468     DOI: 10.1111/all.13599

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  70 in total

Review 1.  Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells.

Authors:  Mark Rusznak; R Stokes Peebles
Journal:  Curr Opin Allergy Clin Immunol       Date:  2019-02

2.  [Nasal provocation with increased ASA dose: improved "non-steroidal anti-inflammatory drugs (NSAIDs)-exacerbated disease" (N‑ERD) detection rate in chronic rhinosinusitis patients].

Authors:  U Förster-Ruhrmann; W Behrbohm; G Pierchalla; A J Szczepek; J W Fluhr; H Olze
Journal:  HNO       Date:  2019-08       Impact factor: 1.284

Review 3.  Current and Future Treatments of Rhinitis and Sinusitis.

Authors:  Gayatri B Patel; Robert C Kern; Jonathan A Bernstein; Park Hae-Sim; Anju T Peters
Journal:  J Allergy Clin Immunol Pract       Date:  2020-01-28

Review 4.  Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases.

Authors:  Ioana Agache; Cezmi A Akdis
Journal:  J Clin Invest       Date:  2019-03-11       Impact factor: 14.808

5.  Effectiveness of endoscopic sinus surgery and aspirin therapy in the management of aspirin-exacerbated respiratory disease.

Authors:  Auddie M Sweis; Tran B Locke; Kevin I Ig-Izevbekhai; Theodore C Lin; Ankur Kumar; Jennifer E Douglas; Andrew M Corr; Alyssa M Civantos; Siddhant H Tripathi; David W Kennedy; Michael A Kohanski; James N Palmer; Nithin D Adappa; John V Bosso
Journal:  Allergy Asthma Proc       Date:  2021-03-01       Impact factor: 2.587

Review 6.  Clinical Evidence of Type 2 Inflammation in Non-allergic Rhinitis with Eosinophilia Syndrome: a Systematic Review.

Authors:  Eugenio De Corso; Veronica Seccia; Giancarlo Ottaviano; Elena Cantone; Daniela Lucidi; Stefano Settimi; Tiziana Di Cesare; Jacopo Galli
Journal:  Curr Allergy Asthma Rep       Date:  2022-02-09       Impact factor: 4.806

7.  Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease.

Authors:  Pooja Patel; Jillian C Bensko; Neil Bhattacharyya; Tanya M Laidlaw; Kathleen M Buchheit
Journal:  Ann Allergy Asthma Immunol       Date:  2021-12-01       Impact factor: 6.347

Review 8.  Formation of nasal polyps: The roles of innate type 2 inflammation and deposition of fibrin.

Authors:  Tetsuji Takabayashi; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2020-03       Impact factor: 10.793

Review 9.  The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.

Authors:  Whitney W Stevens; Elina Jerschow; Alan P Baptist; Larry Borish; John V Bosso; Kathleen M Buchheit; Katherine N Cahill; Paloma Campo; Seong H Cho; Anjeni Keswani; Joshua M Levy; Anil Nanda; Tanya M Laidlaw; Andrew A White
Journal:  J Allergy Clin Immunol       Date:  2020-12-09       Impact factor: 10.793

10.  Regular Treatment With Aspirin 300 mg/day After Desensitization in Patients With N-ERD: 12-Year Results.

Authors:  Saltuk Buğra Kaya; Mehmet Erdem Çakmak; Ebru Damadoğlu; Gül Karakaya; Ali Fuat Kalyoncu
Journal:  Turk Thorac J       Date:  2021-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.